Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2014-09-03
2017-09-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)
NCT02626221
Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria
NCT00525382
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
NCT04109313
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
NCT03436797
Treatment Options for Chronic Urticaria
NCT06816784
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Subject must be refactory to at least one H1 antihistamine
Exclusion Criteria
Subjects taking must not take part in any other concurrent urticarial study.
\-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Plymouth, Devon, United Kingdom
Novartis Investigative Site
Darlington, Durham, United Kingdom
Novartis Investigative Site
Leytonstone, London, United Kingdom
Novartis Investigative Site
Salford, Manchester, United Kingdom
Novartis Investigative Site
Coventry, Warwickshire, United Kingdom
Novartis Investigative Site
Belfast, , United Kingdom
Novartis Investigative Site
Belfast, , United Kingdom
Novartis Investigative Site
Cardiff, , United Kingdom
Novartis Investigative Site
Chester, , United Kingdom
Novartis Investigative Site
Durham, , United Kingdom
Novartis Investigative Site
East Yorkshire, , United Kingdom
Novartis Investigative Site
Kent, , United Kingdom
Novartis Investigative Site
Leeds, , United Kingdom
Novartis Investigative Site
Leicester, , United Kingdom
Novartis Investigative Site
Liverpool, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
Manchester, , United Kingdom
Novartis Investigative Site
Manchester, , United Kingdom
Novartis Investigative Site
Middlesbrough, , United Kingdom
Novartis Investigative Site
Poole, , United Kingdom
Novartis Investigative Site
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIGE025EGB01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.